Keywords: biogen, 2nd-qtr, revenue, up, usa-based, idec, second-quarter
Biogen's 2nd-qtr 2008 revenue up 28%
Article | 04 August 2008
USA-based Biogen Idec's second-quarter 2008 revenues rose 28% year-on-year to $993.0 million, driven by sales of its multiple sclerosis drugs. Avonex (interferon beta-1 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
